At the American Academy of Pain Medicine’s annual meeting last week, Swing presented outcomes data on Swing Care, a specialty clinic for people with fibromyalgia (FM), as well as the results from a pivotal randomized controlled trial of Stanza, its prescription digital therapy for FM.
Results from a chart review of 199 Swing Care patients showed that clinical improvements were observed from Day 30 and increased in later followups, particularly in symptoms that patients most frequently reported to limit their quality of life (QoL), including pain, fatigue, “fibro fog”, difficulty sleeping, and difficulty moving.
The first of its kind, Swing Care is a patient-centered clinic dedicated to virtual fibromyalgia treatment. Patients are treated with a personalized, evidence-based approach combining non-opioid pharmacological and non-drug therapies.
Swing also presented additional data from a pivotal randomized controlled trial (PROSPER-FM) of Stanza, a smartphone-based prescription digital therapy for the treatment of fibromyalgia symptoms. Results showed that positive clinical effects were seen after just a few weeks of digital therapy and tended to increase over the course of therapy, with significant separation from the control arm emerging from weeks 2-4 in all secondary endpoints.
These included improvements in:
- Fibromyalgia Severity (measured by Revised Fibromyalgia Impact Questionnaire (FIQ-R))
- Pain Intensity
- Pain Interference
- Sleep Interference
These findings support that innovations in fibromyalgia care may improve patient outcomes and quality of life. Learn more about Swing Care and its patient-centered approach to fibromyalgia care.
